DHR Health Institute for Research and Development Recognized as a “Top Performing Site” Once Again

Translate to Spanish or other 102 languages!

THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
THREE-PEAT TEAM: The DHR Health Institute for Research and Development pictured here has been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This is the third consecutive time the Institute has received this prestigious recognition. Courtesy image
- Advertisement -

EDINBURG, Texas – The DHR Health Institute for Research and Development is delighted to announce that it has once again been recognized as a “Top Performing Site” by SWOG (formerly the Southwest Oncology Group), one of the nation’s leading cancer clinical trials networks. This marks the third consecutive time the Institute has received this prestigious distinction.

This recognition highlights the ongoing excellence and impact of the Research Institute as it continues to advance cancer research and improve patient outcomes.

“We are deeply honored and this recognition would not be possible without the assistance of the DHR Health Oncology Institute and the leadership of Dr. Jose Cruz,” said Dr. Scott Lillibridge, executive vice president for the DHR Health Institute for Research and Development.

- Advertisement -

SWOG is a global cancer research community supported by the National Cancer Institute (NCI), and recognition as a “Top Performing Site” signifies exceptional performance in clinical trial enrollment, data quality, and patient care standards.

The DHR Health Institute for Research and Development remains committed to innovation and delivering high-quality research opportunities to all residents of the Rio Grande Valley. They are located at 5323 S. McColl Road in Edinburg. For more information about clinical trials in the areas of liver, obesity, cancer, neurology, oncology and urology, call the Institute at (956) 362-2390.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Recognizes November as “National Hospice and Palliative Care” Month

DHR Health is pleased to recognize November as “National Hospice and Palliative Care Month.”  As we highlight National Hospice and Palliative Care Month, let us remember that healthcare is not solely about treating diseases but also about care for people at end of life.

STHS Heart Earns Healthgrades Five-Star Rating for Pacemaker Procedures

Healthgrades, the leading online resource for information about physicians and hospitals, has named STHS Heart a Five-Star Recipient for Pacemaker Procedures in 2027 for the second consecutive year, recognizing the facility's superior clinical outcomes and commitment to patient care.

AMA Advises Patients to Check with Doctors on Web Advice

The internet offers no shortage of health advice. But with misleading medical claims spread across social media, search engines, and AI platforms, finding trustworthy answers can be a challenge. 

FDA Authorizes Focused Ultrasound Treatment for Varicose Veins

Theraclion has announced that the US Food and Drug Administration (FDA) has granted De Novo authorization for its Sonovein device to treat superficial venous reflux in great saphenous veins (GSV), the main cause of varicose veins. This is the first noninvasive focused ultrasound platform to treat varicose veins, which affect approximately one third of adults.
- Advertisement -